Plavix patent trial

Jim Hoy LinkedIn

Bristol-Myers Squibb (NYSE: BMY) is no longer offering its $37-a-month Plavix® Co-Pay Discount Card. Additionally, according to the company’s web site for “Patient Assistance Programs,” the company is no longer making this life-saving drug available to patients who cannot afford it.

The Economics of Irreparable Harm in Pharmaceutical Patent.

This, of course, has something to do with the fact that brand-name Plavix has gone off patent and generic versions have been available since May 2012.

<em>Patent</em> - Services - Cravath, Swaine & Moore LLP

Does Stay Erect Work How Safe Are Penis

Business plans will have to allow for generic competition earlier than previously expected, and particular attention should be paid to the publication of preclinical and clinical data.

7 March 2014 by Gowling Lafleur Henderson LLP This article summarizes noteworthy Canadian patent law decisions and developments from 2013.Canada Patents Year In Review 2013 IP Law Experts

Plavix patent trial:

Rating: 97 / 100

Overall: 99 Rates